Kyu-Sil Choi Selected Research

PD 168368

9/2016	Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells.
12/2011	Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kyu-Sil Choi Research Topics

Disease

7	Neoplasms (Cancer) 01/2016 - 01/2003
4	Inflammation (Inflammations) 09/2015 - 07/2006
3	Breast Neoplasms (Breast Cancer) 09/2016 - 12/2011
2	Experimental Arthritis 03/2015 - 09/2009
2	Hypoxia (Hypoxemia) 01/2005 - 01/2003
1	Atrial Remodeling 01/2017
1	Neoplasm Metastasis (Metastasis) 09/2016
1	Rheumatoid Arthritis 01/2016
1	Nephritis 09/2015
1	Proteinuria 09/2015
1	Dermatitis 09/2015
1	Arthritis (Polyarthritis) 03/2015
1	Wounds and Injuries (Trauma) 11/2013
1	Colonic Neoplasms (Colon Cancer) 02/2013
1	Endotoxemia 12/2009
1	Acute Kidney Injury (Acute Renal Failure) 12/2009
1	Obesity 05/2008
1	Vascular Diseases (Vascular Disease) 05/2008
1	Body Weight (Weight, Body) 07/2006
1	Colitis 07/2006
1	Glioblastoma (Glioblastoma Multiforme) 05/2003
1	Glioma (Gliomas) 05/2003
1	Fibrosarcoma 02/2003

Drug/Important Bio-Agent (IBA)

2	PD 168368IBA 09/2016 - 12/2011
2	Bombesin Receptors (Bombesin Receptor)IBA 09/2016 - 12/2011
2	Therapeutic UsesIBA 01/2016 - 03/2015
2	Pharmaceutical PreparationsIBA 01/2016 - 02/2013
2	GadoliniumIBA 09/2009 - 03/2007
2	AcidsIBA 09/2009 - 03/2007
2	Contrast MediaIBA 09/2009 - 03/2007
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2005 - 01/2003
2	Proteins (Proteins, Gene)FDA Link 01/2005 - 02/2003
2	Peptide Hydrolases (Proteases)FDA Link 05/2003 - 02/2003
2	PlasminogenIBA 05/2003 - 02/2003
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2003 - 02/2003
2	Fibrinolysin FDA Link 05/2003 - 02/2003
1	Connexin 43 (Connexin43)IBA 01/2017
1	ConnexinsIBA 01/2017
1	Cadherins (E-Cadherin)IBA 09/2016
1	VimentinIBA 09/2016
1	CytokinesIBA 01/2016
1	ChemokinesIBA 01/2016
1	Liposomes (Liposome)IBA 01/2016
1	Methotrexate (Mexate)FDA LinkGeneric 01/2016
1	gadobenic acid (gadobenate dimeglumine)FDA Link 01/2016
1	anti-dsDNA autoantibodyIBA 09/2015
1	Collagen Type II (Type II Collagen)IBA 03/2015
1	Saline SolutionIBA 03/2015
1	Phosphates (Orthophosphate)IBA 11/2013
1	ErbB Receptors (EGF Receptor)IBA 02/2013
1	Cetuximab (Erbitux)FDA Link 02/2013
1	cyclic (arginyl- glycyl- aspartyl- phenylalanyl- lysyl)IBA 09/2012
1	IntegrinsIBA 09/2012
1	Peptides (Polypeptides)IBA 12/2011
1	neuromedin BIBA 12/2011
1	BombesinIBA 12/2011
1	Angiopoietin-1IBA 12/2009
1	LipopolysaccharidesIBA 12/2009
1	Cell Adhesion MoleculesIBA 09/2009
1	Nicotinamide PhosphoribosyltransferaseIBA 05/2008
1	AdipokinesIBA 05/2008
1	Gadolinium DTPA (Magnevist)FDA Link 03/2007
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 03/2007
1	Sulfonic AcidsIBA 07/2006
1	Peroxidase (Myeloperoxidase)IBA 07/2006
1	GliotoxinIBA 07/2006
1	NF-kappa B (NF-kB)IBA 07/2006
1	zinc protoporphyrinIBA 07/2006
1	Heme Oxygenase-1IBA 07/2006
1	Transcription Factors (Transcription Factor)IBA 01/2005
1	Messenger RNA (mRNA)IBA 01/2005
1	Oxygen (Dioxygen)IBA 01/2005
1	ElementsIBA 01/2005
1	progelatinaseIBA 05/2003
1	Matrix Metalloproteinases (MMPs)IBA 05/2003
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 05/2003
1	Urokinase Plasminogen Activator ReceptorsIBA 05/2003
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2003

Therapy/Procedure

3	Transplantation 01/2016 - 11/2013
2	Therapeutics 02/2013 - 01/2003
1	Immunomodulation 01/2016
1	Induced Hyperthermia (Thermotherapy) 01/2016
1	Intravenous Injections 09/2013
1	Extracorporeal Shockwave Therapy 02/2013